

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

July 1996

SYNLETT

617

Synthesis of Novel Cationic Lipids with a Guanidine Group. Cationic Lipids 3¹

Igor Solodin, Timothy D. Heath*

School of Pharmacy, University of Wisconsin, 425 N. Charter St., Madison, WI 53706, USA

Received 19 September 1995


Abstract: Potentially cell biodegradable cationic lipids having a strongly basic guanidine group have been prepared by the reaction of lipophilic derivatives of diethanolamine with cyanamide.

Cationic lipids are valuable materials for the preparation of cationic liposomes for drug delivery and gene transfection.² Cationic lipids bear a positively charged head group, which, as a rule consists of a single or multiple nitrogen atoms with variable extents of substitution.³ Other nitrogen containing functionalities also could be involved in the formation of a positively charged head group.⁴ Because of the strongly basic properties (pK_a , 12)⁵ of guanidine, its lipophilic derivatives potentially could serve as a valuable source of cationic lipids.⁶ The method most often used for preparation of guanidine derivatives involves the reaction of amine hydrochlorides with cyanamide.⁷ A number of other guanylating reagents were reported, including O-methylisourea hydrogen sulfate,⁸ S-alkylisothiuronium salts,⁹ salts-of 1*H*-pyrazole-1-carboxamidines,¹⁰ and 1*H*-pyrazole-1-[*N,N*'-bis(*tert*-butyloxycarbonyl)]-carboxamidine.¹¹

For the purpose of successful in vivo gene therapy, it will be essential for the cationic lipid to be biodegradable by cells. Otherwise, accumulation of unmetabolized lipid may cause toxic cell effects. Replacement of the non-metabolizable long-chain aliphatic amine 1 with moieties containing fatty acids linked to the head group by readily metabolized ester bonds seems highly desirable. From this point of view, diethanolamine 3 is a quite suitable starting material (Scheme). After protection of the amino group with the acid labile *tert*-butyloxycarbonyl (BOC) protective group, acylation with the appropriate fatty acid chloride, and removal of the BOC group by treatment with 4M HCl in dioxane, the resulting hydrochloride 6 was reacted with cyanamide in *n*-butanol at 120°C, conditions found to be optimal.

Typical experimental procedure for the preparation of lipophilic guanidines 7^a:

To 2.0 g (0.003 mol) of hydrochloride 6c were added 0.25 g (0.006 mol) of cyanamide and 5.0 ml of *n*-butanol. The resulting mixture was stirred at 120°C for 1.5 hr. Completion of the reaction was monitored by TLC (Merck F₂₅₄ silica gel on glass baked plates, developing solvent: 10% MeOH/90% CHCl₃, spots were visualized by spraying the TLC plate with 4% ethanol solution of phosphomolybdic acid, and heating it on a hotplate at 150°C for 10 min). The cooled mixture was diluted with 100 ml of CHCl₃, washed twice with 5% aqueous NaCl:MeOH/1:1, dried over anhydrous Na₂SO₄, and evaporated on a rotavapor. The residue was purified on a silica gel column using 1-10% MeOH in CHCl₃ as the eluent. After evaporation, 1.11 g (55% yield) of guanidine 7c was obtained as a colorless waxy solid. Some selected data: R_f 0.43; ¹H NMR (300 MHz, CDCl₃) δ 0.88 (m, 2CH₂CH₂, 6H), 1.26, 1.28 (each s, 4 H, 2 (CH₂)₆ and 2 (CH₂)₄); 1.59 (m, 4 H, 2 CH₂CH₂CO); 2.00 (m, 8 H, 2 CH₂CH=CHC₂H₅); 2.31 (m, 4 H, 2 CH₂CH₂CO); 3.76 (m, 4 H, 2 NC₂H₅CH₂O); 4.29 (m, 4 H, 2 NCH₂CH₂O); 5.35 (m, 4 H, 2 CH=CH); 7.54 (br s, 3H, C(=NH)NH₂); ¹³C NMR (75.5 MHz, CDCl₃) δ 173.66, 158.55, 130.01, 129.68, 61.46, 48.89, 33.99, 31.89, 29.71, 29.52, 29.31, 29.19, 29.12, 27.21, 24.71, 22.67, 14.11. Anal. calcd.: C, 69.09; H, 11.05; N, 5.90. Found: C, 69.25; H, 10.91; N, 6.05.



Product	RCO	Yield %
7a	CH ₃ (CH ₂) ₁₂ CO	59
7b	CH ₃ (CH ₂) ₁₄ CO	90
7c	CH ₂ (CH ₂) ₇ CH=CH(CH ₂) ₇ CO	55

Reagents and conditions: a. BOC₂O/CH₂Cl₂, RT. b. RCOCl, NEt₃/CH₂Cl₂, 0°C. c. HCl/dioxane, RT. d. H₂NCN/n-BuOH, 120°.

Scheme. Preparation of Lipophilic Guanidines

Acknowledgments. This work was supported by a grant from Megabios Corp. to TDH.

References and Notes

- Part 2 of this series: Solodin, I.; Brown, C.S.; Heath, T.D. *Synlett* 1996, 457.
- Betageri, G.V.; Jenkins, S.A.; Parsons, D.L. *Liposome Drug Delivery Systems*; Technomic: Lancaster, 1993; Debs, R.J. In *Liposomes as Tools in Basic Research*, Philippot, R.J., Schuber, F., Eds.; CRC: Boca Raton, 1994; p.171; Lasic, D.D. *Liposomes: from Physics to Applications*; Elsevier: Amsterdam, 1993.
- Felgner, P.L.; Gadek, T.R.; Holm, M.; Roman, R.; Chan, H.W.; Wenz, M.; Northrop, J.P.; Ringold, G.M., and Danielsen, M. *Proc. Natl. Acad. Sci. U.S.A.* 1987, 84, 7413. Behr, J.-P.; Denenex, B.; Loesler, J.-P., and Perez-Mutul, J.. *Proc. Natl. Acad. Sci. U.S.A.* 1989, 86, 6982. Farhood, H.,

- Bottega, R., Epand, R.M., and Huang, L. *Biochim. Biophys. Acta* 1992, **1111**, 239. Gao, X. and Huang, L. *Biochem. Biophys. Res. Commun.* 1991, **179**, 280. Rose, J.K., Buonocore, L., and Whitt, M.A. *Biotechniques* 1991, **10**, 520. Hawley-Nelson, P., Ciccarone, V., Gebeyehu, G., and Jesse, J. *Focus* 1993, **15**, 73.
4. Ruysschaert, J.-M., El Ouahabi, A., Willeaume, V., Huez, G., Fuks, R., Vandenbrabden, M., and Di Stefano, P. *Biochem. Biophys. Res. Commun.* 1994, **203**, 1622.
 5. *Guanidines: Historical, Biological, Biochemical, and Clinical Aspects of the Naturally Occurring Guanidino Compounds*; Mori, A., Cohen, B.D., Lowenthal, A., Eds.; Plenum: New York, 1983.
 6. Oleoyl derivative of guanidine 7 has shown high efficiency of gene delivery in cell culture (unpublished results).
 7. Arndt, F., Rosenau, B. *Chem. Ber.* 1917, **50**, 1260. Davis, T.L. *Org. Synth.* 1927, **7**, 46.
 8. Cosand, W.L., Merrifield, R. B. *Proc. Natl. Acad. Sci. U.S.A.* 1977, **74**, 2771. Granier, C., Pedroso, E. M., Vanrietschoten, J. *Eur. J. Biochem.* 1978, **82**, 293.
 9. Braun, C.E. *J. Am. Chem. Soc.* 1933, **55**, 1280. King, H., Tonkin, S.M. *J. Chem. Soc.* 1946, 1063. Jen, T., Van Hoeven, H., Groves, W., McLean, R. A., Loev, B. *J. Med. Chem.* 1975, **18**, 90. Maryanoff, B. E., Tutwiler, G. F. *Annu. Rep. Med. Chem.* 1981, **16**, 173.
 10. Bannard, R. A. B., Casselman, A.A., Cockburn, W.F., Brown, G. M. *Can. J. Chem.* 1958, **36**, 1541. Bernatowicz, M.S., Wu, Y., Matsueda, G. R. *J. Org. Chem.* 1992, **57**, 2497.
 11. Bernatowicz, M.S., Wu, Y., Matsueda, G. R. *Tetrahedron Lett.* 1993, **34**, 3389. Drake, B., Patek, M., Lebl, M. *Synthesis*, 1994, 579.
 12. All products were fully characterized by appropriate spectral data and elemental analysis.